Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Nacer Abrouk"'
Autor:
Bryan Oronsky, Erica Burbano, Meaghan Stirn, Joanne Brechlin, Nacer Abrouk, Scott Caroen, Angelique Coyle, Jeannie Williams, Pedro Cabrales, Tony R. Reid
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 9, Pp 1497-1509 (2023)
Abstract In drug development a frequently used phrase is “data‐driven”. Just as high‐test gas fuels a car, so drug development “runs on” high‐quality data; hence, good data management practices, which involve case report form design, da
Externí odkaz:
https://doaj.org/article/70093a437cb04467ae0f11efeab45dfb
Autor:
Anthony Conley, Tony Reid, Santosh Kesari, Jeannie Williams, Christopher Larson, Bryan Oronsky, Meaghan Stirn, Erica Burbano, Nacer Abrouk
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/d4775a354e2a4d87a0d14d4a5c83ca61
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe current standard of care for newly diagnosed glioblastoma (GBM) is maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and radiotherapy (RT) and then six to twelve cycles of maintenance TMZ. RRx-001, an
Externí odkaz:
https://doaj.org/article/627cab8b43e94cfa99de92b3157c611b
Autor:
Tony Reid, Bryan Oronsky, Scott Caroen, Mary Quinn, Jeannie Williams, Pedro Cabrales, Nacer Abrouk
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundBromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor that has been observed, in experimental systems, to also downregulate CD47, repolarize tumor associated macrophages (TAMs) and normalize aberrant tumor perfusion. This phase 1
Externí odkaz:
https://doaj.org/article/6bc48b56408349eb8cecef4adf30d433
Autor:
Bryan, Oronsky, Nacer, Abrouk, Scott, Caroen, Michelle, Lybeck, Xiaoning, Guo, Xiaohui, Wang, Zhongwen, Yu, Tony, Reid
Publikováno v:
Journal of Cancer. 13:2945-2953
For close to 40 years small-cell lung cancer (SCLC) was adrift, as listless, and as idle as a painted ship on a painted ocean, with nary a breeze to blow in the direction of clinical progress or change. The preferred decades-old first line regimen wa
Autor:
Marcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, Kyle Colvett, Vinita Takiar, Matthew Biagioli, Voichita Bar-Ad, Sharad Goyal, Brian Muzyka, Kenneth Niermann, Nacer Abrouk, Bryan Oronsky, Tony Reid, Scott Caroen, Stephen Sonis, David J. Sher
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics.
Autor:
Xiaohui Wang, S. Scott Caroen, Bryan T. Oronsky, Xiaoning Guo, Tony R. Reid, David J. Sher, Michelle Lybeck, Lou Cannizzo, Bob Wardle, Nacer Abrouk, Arnold L. Oronsky, Pedro Cabrales
Publikováno v:
Journal of Medicinal Chemistry. 64:7261-7271
After extensive screening of aerospace compounds in an effort to source a novel anticancer agent, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development. RRx-001 is a minimall
Autor:
Tony R. Reid, Nacer Abrouk, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Christopher Larson, Keola Beale, Susan J. Knox, George Fisher
Publikováno v:
Clinical colorectal cancer.
RRx-001 is a novel cysteine-targeted alkylating agent that releases nitric oxide (NO). The primary biological activities of this hybrid molecule include macrophage repolarizing and vascular normalization. The purpose of this clinical trial (ROCKET) (
Publikováno v:
Journal of Clinical Oncology. 41:657-657
657 Background: RRx-001 is a small molecule anticancer agent that preclinically protects non-malignant tissues, but not tumors, against the cytotoxicities of chemotherapy and radiation. In a completed, multicenter Phase 2 trial, QUADRUPLE THREAT, pat
Publikováno v:
Journal of Clinical Oncology. 41:97-97
97 Background: RRx-001 is a novel cysteine-targeted alkylating agent that, upon binding, under severe hypoxia, which is primarily present in tumors, releases nitric oxide (NO) and other cytotoxic metabolites. The primary biological activities of this